ArticleACS materials Au2023
Modified Poly(ε-caprolactone) with Tunable Degradability and Improved Biofunctionality for Regenerative Medicine.
Article in ACS materials Au, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Understanding Polycaprolactone Degradation: Molecular Mechanisms and Implications for Biomedical Device Design.Materials (Basel, Switzerland) · 2026Review
- Feasibility of Polylactic Acid-Polycaprolactone-Blended Microspheres in Transarterial Embolization Therapy.ACS omega · 2026Article
- Biodegradable synthetic polymers for biomedical and tissue engineering applications: tailoring degradation kinetics with tissue regeneration timeline.Biomedical engineering online · 2026Review
- Electro-Stimulated Graphene-Polymer Nanocomposites Enable Wearable Patches With Feedback-Controlled Drug Release.Advanced healthcare materials · 2026Article
- Atomistic Insights into Structure and Properties of ε-Caprolactone Oligomers.The journal of physical chemistry. B · 2026Article
- Synthetic Polymer-Based Interventions in Wound Healing: A Clinical Perspective on their Efficacy and Limitations.Current pharmaceutical design · 2026Review
- A novel method for targeting lymphatic vessel imaging: methylene blue nanoparticle integrated with dissolvable microneedles.Burns & trauma · 2026Article
- Long-Gap Sciatic Nerve Regeneration Using 3D-Printed Nerve Conduits with Controlled FGF-2 Release.ACS applied materials & interfaces · 2025Article
- Synthesis and use of thermoplastic polymers for tissue engineering purposes.International journal of pharmaceutics: X · 2025Review
- Article
- Melt Electrowriting of Polyhydroxyalkanoates for Enzymatically Degradable Scaffolds.Advanced healthcare materials · 2025Article
- Hydrogel-Enhanced Autologous Chondrocyte Implantation for Cartilage Regeneration-An Update on Preclinical Studies.Bioengineering (Basel, Switzerland) · 2024Review
- Innovations in Bioengineering Virtual Special Issue.ACS materials Au · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of poly(ε-caprolactone) (PCL) for biomedical applications is well established, particularly for permanent implants, due to its slow degradation rate, suitable mechanical properties, and biocompatibility. However, the slow degradation rate of PCL limits its application for short-term and temporary biomedical applications where bioabsorbability is required. To enhance the properties of PCL and to expand its biomedical applications, we developed an approach to produce PCL membranes with tunable degradation rates, mechanical properties, and biofunctional features. Specifically, we utilized electrospinning to create fibrous PCL membranes, which were then chemically modified using potassium permanganate to alter their degradability while having minimal impact on their fibrous morphology. The effects of the chemical treatments were investigated by treating the samples for different time periods ranging from 6 to 48 h. After the 48 h treatment, the membrane degraded by losing 25% of its mass over 12 weeks in degradation studies, while maintaining its mechanical strength and exhibiting superior biofunctional features. Our results suggest that this approach for developing PCL with tailored properties could have significant potential for a range of biomedical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.